Use of SERMs for treatment in postmenopausal women

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 142-154

  Pinkerton, Joann V ^a   Thomas, Semara ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; Cardiovascular; Endometrium; Estrogen agonist; Estrogen antagonist; Hot flashes; Osteoporosis; SERMs; TSEC; Vaginal atrophy

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE; BRAIN; BREAST; BREAST CANCER; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG USE; DYSPAREUNIA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FOOD AND DRUG ADMINISTRATION; HOT FLUSH; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; VAGINA; VAGINA ATROPHY; VEIN THROMBOSIS;

EQUIDAE;

BREAST CANCER; CARDIOVASCULAR; ENDOMETRIUM; ESTROGEN AGONIST; ESTROGEN ANTAGONIST; HOT FLASHES; OSTEOPOROSIS; SERMS; TSEC; VAGINAL ATROPHY;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DYSPAREUNIA; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PYRROLIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TETRAHYDRONAPHTHALENES; TOREMIFENE;

EID: 84899896223     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.12.011     Document Type: Review

References (109)

1. D.P. McDonnell, D.L. Clemm, T. Hermann, M.E. Goldman, and J.W. Pike Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens Mol. Endocrinol. 9 1995 659 669
2. C.L. Smith, Z. Nawaz, and B.W. O'Malley Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol. Endocrinol. 11 1997 657 666
3. A.K. Shiau, D. Barstad, P.M. Loria, L. Cheng, P.J. Kushner, D.A. Agard, and G.L. Greene The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 1998 927 937
4. P.Y. Maximov, T.M. Lee, and V.C. Jordan The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice Curr. Clin. Pharmacol. 8 2013 135 155
5. B.L. Clarke, and S. Khosla New selective estrogen and androgen receptor modulators Curr. Opin. Rheumatol. 21 2009 374 379
6. M. Amita, T. Takahashi, S. Tsutsumi, T. Ohta, K. Takata, N. Henmi, S. Hara, H. Igarashi, K. Takahashi, and H. Kurachi Molecular mechanism of the inhibition of estradiol-induced endometrial epithelial cell proliferation by clomiphene citrate Endocrinology 151 2010 394 405
7. D.M. Lonard, and B.W. O'Malley The expanding cosmos of nuclear receptor coactivators Cell 125 2006 411 414
8. M. Dutertre, and C.L. Smith Molecular mechanisms of selective estrogen receptor modulator (SERM) action J. Pharmacol. Exp. Ther. 295 2000 431 437
9. H.S. Taylor Designing the ideal selective estrogen receptor modulator - an achievable goal? Menopause 16 2009 609 615
10. M.K. Tee, I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R.J. Christy, K.R. Yamamoto, and D.C. Leitman Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta Mol. Biol. Cell 15 2004 1262 1272
11. D.P. McDonnell The molecular determinants of estrogen receptor pharmacology Maturitas 48 Suppl. 1 2004 S7 S12
12. B.L. Riggs, and L.C. Hartmann Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N. Engl. J. Med. 348 2003 618 629
13. J.M. Hall, and D.P. McDonnell Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting Mol. Interv. 5 2005 343 357
14. L. Bjornstrom, and M. Sjoberg Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes Mol. Endocrinol. 19 2005 833 842
15. J.V. Pinkerton, and F.Z. Stanczyk Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy Menopause 2013 (Epub ahead of print, June 18)
16. J.V. Pinkerton, J.H. Pickar, J. Racketa, and S. Mirkin Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention Climacteric 15 2012 411 418
17. J.V. Pinkerton, and S.R. Goldstein Endometrial safety: a key hurdle for selective estrogen receptor modulators in development Menopause 17 2010 642 653
18. E.R. Nelson, S.E. Wardell, and D.P. McDonnell The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis Bone 53 2013 42 50
19. S.R. Cummings, K. Ensrud, P.D. Delmas, A.Z. LaCroix, S. Vukicevic, D.M. Reid, S. Goldstein, U. Sriram, A. Lee, J. Thompson, R.A. Armstrong, D.D. Thompson, T. Powles, J. Zanchetta, D. Kendler, P. Neven, and R. Eastell Lasofoxifene in postmenopausal women with osteoporosis N. Engl. J. Med. 362 2010 686 696
20. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
21. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, J.A. Cauley, L. Norton, T. Nickelsen, N.H. Bjarnason, M. Morrow, M.E. Lippman, D. Black, J.E. Glusman, A. Costa, and V.C. Jordan The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial JAMA 281 1999 2189 2197
22. S. Martino, J.A. Cauley, E. Barrett-Connor, T.J. Powles, J. Mershon, D. Disch, R.J. Secrest, S.R. Cummings, and CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J. Natl. Cancer Inst. 96 2004 1751 1761
23. B.S. Komm, Y.P. Kharode, P.V. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 146 2005 3999 4008
24. V.G. Vogel, J.P. Costantino, D.L. Wickerham, W.M. Cronin, R.S. Cecchini, J.N. Atkins, T.B. Bevers, L. Fehrenbacher, E.R. Pajon Jr., J.L. Wade III, A. Robidoux, R.G. Margolese, J. James, S.M. Lippman, C.D. Runowicz, P.A. Ganz, S.E. Reis, W. Caskill-Stevens, L.G. Ford, V.C. Jordan, and N. Wolmark Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
25. R. Gu, W. Jia, Y. Zeng, N. Rao, Y. Hu, S. Li, J. Wu, L. Jin, L. Chen, M. Long, K. Chen, L. Chen, Q. Xiao, M. Wu, E. Song, and F. Su A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study BMC Cancer 12 2012 161
26. T.L. Taras, G.T. Wurz, and M.W. DeGregorio In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer J. Steroid Biochem. Mol. Biol. 77 2001 271 279
27. R.A. Burich, N.R. Mehta, G.T. Wurz, J.L. McCall, B.E. Greenberg, K.E. Bell, S.M. Griffey, and M.W. DeGregorio Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model Menopause 19 2012 96 103
28. J. Komi, K.S. Lankinen, M. DeGregorio, J. Heikkinen, S. Saarikoski, M. Tuppurainen, K. Halonen, R. Lammintausta, K. Vaananen, O. Ylikorkala, and R. Erkkola Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J. Bone Miner. Metab. 24 2006 314 318
29. P.D. Miller, A.A. Chines, C. Christiansen, H.C. Hoeck, D.L. Kendler, E.M. Lewiecki, G. Woodson, A.B. Levine, G. Constantine, and P.D. Delmas Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J. Bone Miner. Res. 23 2008 525 535
30. B.S. Komm, and A.A. Chines Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis Ther. Adv. Musculoskelet. Dis. 4 2012 21 34
31. J.H. Pickar, T. MacNeil, and K. Ohleth SERMs: progress and future perspectives Maturitas 67 2010 129 138
32. B.A. Mincey, T.J. Moraghan, and E.A. Perez Prevention and treatment of osteoporosis in women with breast cancer Mayo Clin. Proc. 75 2000 821 829
33. B.L. Riggs, and L.J. Melton III Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density J. Bone Miner. Res. 17 2002 11 14
34. R.S. Braithwaite, R.T. Chlebowski, J. Lau, S. George, R. Hess, and N.F. Col Meta-analysis of vascular and neoplastic events associated with tamoxifen J. Gen. Intern. Med. 18 2003 937 947
35. A.A. Onitilo, P. Kar, J.M. Engel, and I. Glurich Long-term cardiac and vascular disease outcomes following adjuvant tamoxifen therapy: current understanding of impact on physiology and overall survival Minerva Med. 104 2013 141 153
36. T. Simon, P. Boutouyrie, J.M. Simon, B. Laloux, C. Tournigand, A.I. Tropeano, S. Laurent, and P. Jaillon Influence of tamoxifen on carotid intima-media thickness in postmenopausal women Circulation 106 2002 2925 2929
37. P. Collins, L. Mosca, M.J. Geiger, D. Grady, M. Kornitzer, M.G. mewou-Atisso, M.B. Effron, S.A. Dowsett, E. Barrett-Connor, and N.K. Wenger Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors Circulation 119 2009 922 930
38. E. Barrett-Connor, L. Mosca, P. Collins, M.J. Geiger, D. Grady, M. Kornitzer, M.A. McNabb, and N.K. Wenger Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N. Engl. J. Med. 355 2006 125 137
39. K. Ensrud, A. LaCroix, J.R. Thompson, D.D. Thompson, R. Eastell, D.M. Reid, S. Vukicevic, J. Cauley, E. Barrett-Connor, R. Armstrong, F. Welty, and S. Cummings Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial Circulation 122 2010 1716 1724
40. J.A. Simon, V.H. Lin, C. Radovich, G.A. Bachmann Ospemifene Study Group One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus Menopause 20 2012 418 427
41. T.J. De Villiers Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women Climacteric 12 Suppl. 1 2009 108 111
42. A. Decensi, P. Maisonneuve, N. Rotmensz, D. Bettega, A. Costa, V. Sacchini, A. Salvioni, R. Travaglini, P. Oliviero, G. D'Aiuto, M. Gulisano, G. Gucciardo, M.R. del Turco, M.A. Pizzichetta, S. Conforti, B. Bonanni, P. Boyle, and U. Veronesi Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation 111 2005 650 656
43. S.L. Silverman, C. Christiansen, H.K. Genant, S. Vukicevic, J.R. Zanchetta, T.J. De Villiers, G.D. Constantine, and A.A. Chines Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial J. Bone Miner. Res. 23 2008 1923 1934
44. G.A. Bachmann, and J.O. Komi Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause 17 2010 480 486
45. J.L. McCall, and M.W. DeGregorio Pharmacologic evaluation of ospemifene Expert Opin. Drug Metab. Toxicol. 6 2010 773 779
46. L. Zhao, K. O'Neill, and B.R. Diaz Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs Brain Res. Brain Res. Rev. 49 2005 472 493
47. L.L. DonCarlos, I. Azcoitia, and L.M. Garcia-Segura Neuroprotective actions of selective estrogen receptor modulators Psychoneuroendocrinology 34 Suppl. 1 2009 S113 S122
48. M.A. Arevalo, M. Santos-Galindo, N. Lagunas, I. Azcoitia, and L.M. Garcia-Segura Selective estrogen receptor modulators as brain therapeutic agents J. Mol. Endocrinol. 46 2011 R1 R9
49. D.J. Portman, G.A. Bachmann, and J.A. Simon Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy Menopause 20 2013 623 630
50. L. Gennari Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy Expert Opin. Pharmacother. 10 2009 2209 2220
51. F.J. Cohen, and Y. Lu Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials Maturitas 34 2000 65 73
52. C. Bouchard Selective estrogen receptor modulators and their effects on hot flashes: a dilemma Menopause 18 2011 477 479
53. D.G. Hattersley, S. Paquin, and S. Ho RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms Presented at the 89th Annual Meeting of the Endocrine Society, June 2-5 Toronto, Canada 2007
54. D.W. Stovall, W. Utian, M. Gass, Y. Qu, D. Muram, M. Wong, and L. Plouffe Jr. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety Menopause 14 2007 510 517
55. A. Nath, and R. Sitruk-Ware Pharmacology and clinical applications of selective estrogen receptor modulators Climacteric 12 2009 188 205
56. ® (tamoxifen citrate) Prescribing Information. AstraZeneca.
57. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, A. Robidoux, T.B. Bevers, M.T. Kavanah, J.N. Atkins, R.G. Margolese, C.D. Runowicz, J.M. James, L.G. Ford, and N. Wolmark Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 97 2005 1652 1662
58. C.K. Osborne Tamoxifen in the treatment of breast cancer N. Engl. J. Med. 339 1998 1609 1618
59. C. Davies, J. Godwin, R. Gray, M. Clarke, D. Cutter, S. Darby, P. McGale, H.C. Pan, C. Taylor, Y.C. Wang, M. Dowsett, J. Ingle, R. Peto Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
60. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, and P. Boyle Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296 300
61. C. Davies, H. Pan, J. Godwin, R. Gray, R. Arriagada, V. Raina, M. Abraham, V.H. Alencar, A. Badran, X. Bonfill, J. Bradbury, M. Clarke, R. Collins, S.R. Davis, A. Delmestri, J.F. Forbes, P. Haddad, M.F. Hou, M. Inbar, H. Khaled, J. Kielanowska, W.H. Kwan, B.S. Mathew, I. Mittra, B. Muller, A. Nicolucci, O. Peralta, F. Pernas, L. Petruzelka, T. Pienkowski, R. Radhika, B. Rajan, M.T. Rubach, S. Tort, G. Urrutia, M. Valentini, Y. Wang, and R. Peto Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
62. T.J. Powles, T. Hickish, J.A. Kanis, A. Tidy, and S. Ashley Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women J. Clin. Oncol. 14 1996 78 84
63. R.R. Love, R.B. Mazess, H.S. Barden, S. Epstein, P.A. Newcomb, V.C. Jordan, P.P. Carbone, and D.L. DeMets Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N. Engl. J. Med. 326 1992 852 856
64. L. Vehmanen, I. Elomaa, C. Blomqvist, and T. Saarto Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status J. Clin. Oncol. 24 2006 675 680
65. A. Sverrisdottir, T. Fornander, H. Jacobsson, S.E. von, and L.E. Rutqvist Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy J. Clin. Oncol. 22 2004 3694 3699
66. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer Inst. 86 1994 527 537
67. R.E. Curtis, D.M. Freedman, M.E. Sherman, and J.F. Fraumeni Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer J. Natl. Cancer Inst. 96 2004 70 74
68. M. Saadat, P.T. Truong, H.A. Kader, C.H. Speers, E. Berthelet, E. McMurtrie, and I.A. Olivotto Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen Cancer 110 2007 31 37
69. A.E. Bland, B. Calingaert, A.A. Secord, P.S. Lee, F.A. Valea, A. Berchuck, J.T. Soper, and L. Havrilesky Relationship between tamoxifen use and high risk endometrial cancer histologic types Gynecol. Oncol. 112 2009 150 154
70. W.E. Hoogendoorn, H. Hollema, H.H. van Boven, E. Bergman, G. de Leeuw-Mantel, I. Platteel, R. Fles, P.M. Nederlof, M.J. Mourits, and F.E. Van Leeuwen Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer Breast Cancer Res. Treat. 112 2008 99 108
71. A.J. Swerdlow, and M.E. Jones Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study J. Natl. Cancer Inst. 97 2005 375 384
72. S.R. Deitcher, and M.P. Gomes The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review Cancer 101 2004 439 449
73. H.A. Harvey, M. Kimura, and A. Hajba Toremifene: an evaluation of its safety profile Breast 15 2006 142 157
74. M. Gershanovich, A. Garin, D. Baltina, A. Kurvet, L. Kangas, and J. Ellmen A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group Breast Cancer Res. Treat. 45 1997 251 262
75. D.F. Hayes, J.A. Van Zyl, A. Hacking, L. Goedhals, W.R. Bezwoda, J.A. Mailliard, S.E. Jones, C.L. Vogel, R.F. Berris, and I. Shemano Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer J. Clin. Oncol. 13 1995 2556 2566
76. S. Pyrhonen, R. Valavaara, H. Modig, M. Pawlicki, T. Pienkowski, S. Gundersen, J. Bauer, G. Westman, S. Lundgren, G. Blanco, O. Mella, I. Nilsson, T. Hietanen, I. Hindy, J. Vuorinen, and A. Hajba Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study Br. J. Cancer 76 1997 270 277
77. Medications for Risk Reduction of Primary Breast Cancer in Women 2013 US Preventative Services Task Force Available at: www. uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm (accessed 25.11.13)
78. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, H.K. Genant, C. Christiansen, P.D. Delmas, J.R. Zanchetta, J. Stakkestad, C.C. Gluer, K. Krueger, F.J. Cohen, S. Eckert, K.E. Ensrud, L.V. Avioli, P. Lips, and S.R. Cummings Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645
79. M. Maricic, J.D. Adachi, S. Sarkar, W. Wu, M. Wong, and K.D. Harper Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis Arch. Intern. Med. 162 2002 1140 1143
80. J.A. Kanis, O. Johnell, D.M. Black, R.W. Downs Jr., S. Sarkar, T. Fuerst, R.J. Secrest, and I. Pavo Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial Bone 33 2003 293 300
81. P.D. Delmas, H.K. Genant, G.G. Crans, J.L. Stock, M. Wong, E. Siris, and J.D. Adachi Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial Bone 33 2003 522 532
82. S.A. Foster, N. Shi, S. Curkendall, J. Stock, B.C. Chu, R. Burge, D.R. Diakun, and J.H. Krege Fractures in women treated with raloxifene or alendronate: a retrospective database analysis BMC Womens Health 13 2013 15
83. A. DeMichele, A.B. Troxel, J.A. Berlin, A.L. Weber, G.R. Bunin, E. Turzo, R. Schinnar, D. Burgh, M. Berlin, S.C. Rubin, T.R. Rebbeck, and B.L. Strom Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study J. Clin. Oncol. 26 2008 4151 4159
84. A. Parsons, D. Merritt, A. Rosen, H. Heath III, S. Siddhanti, and L. Plouffe Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy Obstet. Gynecol. 101 2003 346 352
85. J.V. Pinkerton, J.L. Shifren, V.J. La, A. Rosen, M. Roesinger, and S. Siddhanti Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women Menopause 10 2003 45 52
86. J. Komi, K.S. Lankinen, P. Harkonen, M.W. DeGregorio, S. Voipio, S. Kivinen, R. Tuimala, T. Vihtamaki, K. Vihko, O. Ylikorkala, and R. Erkkola Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause 12 2005 202 209
87. P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, M. Draper, and C. Christiansen Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 337 1997 1641 1647
88. E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, K. Hoszowski, P. Rautaharju, and K.D. Harper Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial JAMA 287 2002 847 857
89. K. Yaffe, K. Krueger, S.R. Cummings, T. Blackwell, V.W. Henderson, S. Sarkar, K. Ensrud, and D. Grady Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial Am. J. Psychiatry 162 2005 683 690
90. M.A. Espeland, S.A. Shumaker, M. Limacher, S.R. Rapp, T.B. Bevers, D.H. Barad, L.H. Coker, S.A. Gaussoin, M.L. Stefanick, D.S. Lane, P.M. Maki, and S.M. Resnick Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition J. Womens Health (Larchmt) 19 2010 371 379
91. S.L. Silverman, A.A. Chines, D.L. Kendler, A.W. Kung, C.S. Teglbjaerg, D. Felsenberg, N. Mairon, G.D. Constantine, and J.D. Adachi Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos. Int. 23 2012 351 363
92. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2010 281 289
93. L. Kangas, and M. Unkila Tissue selectivity of ospemifene: pharmacologic profile and clinical implications Steroids 78 2013 1273 1280
94. O. Ylikorkala, B. Cacciatore, K. Halonen, R. Lassila, R. Lammintausta, E.M. Rutanen, J. Heikkinen, and J. Komi Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women Menopause 10 2003 440 447
95. A. Buzdar, D. Hayes, A. El-Khoudary, S. Yan, P. Lonning, M. Lichinitser, R. Gopal, G. Falkson, K. Pritchard, A. Lipton, K. Wolter, A. Lee, K. Fly, R. Chew, M. Alderdice, K. Burke, and P. Eisenber Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer Breast Cancer Res. Treat. 73 2002 161 175
96. T.E. Vogelvang, M.J. van der Mooren, V. Mijatovic, and P. Kenemans Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women Drugs 66 2006 191 221
97. W. Shelly, M.W. Draper, V. Krishnan, M. Wong, and R.B. Jaffe Selective estrogen receptor modulators: an update on recent clinical findings Obstet. Gynecol. Surv. 63 2008 163 181
98. S.R. Goldstein, and N. Nanavati Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study Am. J. Obstet. Gynecol. 187 2002 521 527
99. P.N. Munster Arzoxifene: the development and clinical outcome of an ideal SERM Expert Opin. Investig. Drugs 15 2006 317 326
100. S.R. Goldstein, H.P. Bhattoa, P. Neven, D.A. Cox, S.A. Dowsett, J. Alam, A. Sipos, and D. Muram Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass Menopause 19 2012 41 47
101. S. Mirkin, B.S. Komm, K. Pan, and A.A. Chines Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric 16 2013 338 346
102. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 2009 1116 1124
103. R.A. Lobo, J.V. Pinkerton, M.L.S. Gass, M.H. Dorin, S. Ronkin, J.H. Pickar, and G. Constantine Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile Fertil. Steril. 92 2009 1025 1038
104. J.H. Pickar, I.-T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil. Steril. 92 2009 1018 1024
105. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women Fertil. Steril. 92 2009 1045 1052
106. J.A. Harvey, J.V. Pinkerton, E.C. Baracat, H. Shi, A.A. Chines, and S. Mirkin Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens Menopause 20 2013 138 145
107. J.V. Pinkerton, J.A. Harvey, K. Pan, J.R. Thompson, K.A. Ryan, A.A. Chines, and S. Mirkin Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial Obstet. Gynecol. 121 2013 959 968
108. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertil. Steril. 92 2009 1039 1044
109. J.V. Pinkerton, B.S. Komm, and S. Mirkin Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model Climacteric 16 2013 618 628